Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Extratumoral biological determinants that decrease survival in older adults with glioblastoma

Award Number: R01NS129835
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/19/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Extratumoral biological determinants that decrease survival in older adults with glioblastoma - PROJECT SUMMARY Wild-type isocitrate dehydrogenase 1/2 glioblastoma (GBM) is the most common and aggressive form of malignant primary brain tumor in adults with a median age of onset at 68-70 years old. IDHwt GBM patients represent >70% of all GBM patient diagnoses, and among those individuals, older adults ≥65 years of age have a significantly decreased median overall survival (mOS) as compared to younger IDHwt GBM patients after treatment with standard of care radiation (RT) and temozolomide. We have also studied our ongoing clinical trial NCT04047706 and determined that newly-diagnosed older adult IDHwt MGMT promoter unmethylated GBM patients who are treated with RT, nivolumab (PD-1 mAb), and BMS-986205 [IDO enzyme inhibitor (IDOi)] have a decreased mOS as compared to similarly-treated younger GBM patients (p<0.0007). Strikingly, >33% of the youngest patients in this trial are still alive at 36 months post-treatment initiation. The poor prognosis of older adult GBM patients starkly contrasts with individuals who undergo treatment for other forms of aggressive cancer that arises outside of the brain. For example, former President Jimmy Carter was diagnosed with metastatic melanoma at 91 years of age and subsequently treated with immunotherapy. Strikingly, President Carter is still alive today at 98 years old. We hypothesize that major contributing factors to the worse survival outcomes of older adult GBM patients depend on: (i) how intratumoral gene expression levels do not change with differences in GBM patient age [Shah et al., 2021, Cell Reports. 37(10):110100], but rather, (ii) how extratumoral levels of immunosuppression increase in the older adult brain and potently suppress therapeutic efficacy in older adults with GBM [Ladomersky…Wainwright, 2020, Clinical Cancer Research. 26(19):5232-5245], and (iii) how extratumoral levels of senescence increase in the older adult brain [Kim…Wainwright, 2021, Neuro-Oncology Advances. 3(1):vdab125]. To understand the effects of advanced age-mediated changes in the extratumoral older adult brain, that in-turn, promotes the maladaptive response to GBM and/or GBM treatments, we will: (i) study extratumoral IDO-mediated immunosuppression of therapeutic efficacy in older adult mice with GBM; (ii) characterize extratumoral senescence levels and their effects on survival outcomes of older adult mice with GBM; (iii) quantify aging parameters in the extratumoral human brain from individuals across the lifespan that did or did not have GBM. This research is highly innovative and significant for its goal to understand aging- dependent mechanisms that contribute to worse survival outcomes in older adults with IDHwt GBM.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $385,000 )
2026	2026	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	4/27/2026	NON-COMPETING CONTINUATION	$385,000
														Subtotal = $385,000

Issue Date FY: 2025 ( Subtotal = $385,000 )
2025	2025	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	4/11/2025	NON-COMPETING CONTINUATION	$385,000
														Subtotal = $385,000

Issue Date FY: 2024 ( Subtotal = $373,450 )
2024	2024	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	4/29/2024	NON-COMPETING CONTINUATION	$373,450
														Subtotal = $373,450

Issue Date FY: 2023 ( Subtotal = $385,000 )
2023	2023	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	8/18/2023	NEW	$385,000
														Subtotal = $385,000

Grand Total All Awards = $1,528,450

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Extratumoral biological determinants that decrease survival in older adults with glioblastoma

Award Number: R01NS129835

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/19/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer